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background Since direct-acting antivirals (DAAs) have 
been approved for the treatment of hepatitis C virus 
(HCV) infection, a small series of patients with new-onset 
neuropsychiatric alterations have been referred to us. We 
therefore set out to study neuropsychiatric function in 
relation to DAAs prospectively.
Methods Ten patients with cirrhosis and 12 post-
liver transplant (post-LT) patients were enrolled. All 
underwent wake electroencephalography (EEG) and a 
neuropsychological evaluation (paper and pencil battery, 
simple/choice reaction times, working memory task) at 
baseline, at the end of treatment with DAAs and after  
6 months. At the same time points, full blood count, liver/
kidney function tests, quantitative HCV RNA, ammonia 
and immunosuppressant drug levels were obtained, as 
appropriate.
results Patients with cirrhosis were significantly older 
than post-LT patients (65±12 vs 55±7 years; P<0.05). 
Neuropsychological performance and wake EEG were 
comparable in the two groups at baseline. At the end of 
a course of treatment with DAAs, a significant slowing in 
choice reaction times and in the EEG (increased relative 
delta power) was observed in patients with cirrhosis, 
which resolved after 6 months. In contrast, no significant 
changes over time were observed in the neuropsychiatric 
performance of post-LT patients. No significant 
associations were observed between neuropsychiatric 
performance and stand-alone/combined laboratory 
variables.
Conclusion Some degree of neuropsychiatric impairment 
was observed in relation to treatment with DAAs in 
patients with cirrhosis, but not in post-LT patients, 
suggesting that the former may be sensitive to mild DAA 
neurotoxicity.
IntroductIon
The recent approval of highly effective and 
well-tolerated direct-acting antiviral (DAA) 
regimens has dramatically changed the 
approach to hepatitis C virus (HCV) infec-
tion management. Over the last few years, 
several prospective trials have proven the 
effectiveness of DAAs in both patients with 
cirrhosis1–3 and transplanted patients with 
HCV recurrence.3–5 For the majority of the 
all-oral anti-HCV DAAs approved regimens, 
sofosbuvir (SOF) represents the pangeno-
typic backbone of the combination therapy, 
acting as a nucleotide analogue that inhibits 
the NS5B protein of HCV.6 
In Italy, SOF was approved at the end of 
December 2014, and over the subsequent 
year two further drugs were approved, namely 
simeprevir and ledipasvir. Over the first few 
months after the introduction of DAAs in 
our clinical practice, a number of patients on 
antiviral therapy (eight with cirrhosis and one 
postliver transplant (post-LT)) were referred 
to author SM for formal neuropsychiatric 
evaluation because of new-onset alterations/
hepatic encephalopathy. While no obvious 
causal relationships could be established, it is 
of interest that all eight patients with cirrhosis 
had no history of overt hepatic encephalop-
athy, and only two had experienced some 
summary box
What is already known about this topic?
 ► Limited information is available on the effects of 
direct-acting antivirals on cognitive performance.
What are the new findings?
 ► We report mild, transient worsening in cognitive 
and neurophysiological performance in patients 
with cirrhosis at the end of a course of treatment 
with a sofosbuvir-based regimen.
 ► No such changes were observed in a group of 
younger but otherwise comparable patients treated 
for post-liver transplantation hepatitis C recurrence.
How might it impact on clinical practice in the 
foreseeable future?
 ► Caution may be needed when treating patients 
with cirrhosis with sofosbuvir-based regimens, 
especially if there is a history of hepatic 
encephalopathy and/or neurological or psychiatric 
comorbidity.
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degree of deterioration in liver function while on DAAs. 
Referrals came from four different clinicians working in 
different departments, three of whom raised the possi-
bility of drug-related neurotoxicity based on the observed 
time course of symptoms development. We therefore 
set out to study neuropsychiatric function in relation to 
DAAs prospectively.
PatIents and methods
Twenty-two consecutive patients, 10 with HCV-related 
cirrhosis (40% male; age 65±12, all Child A, average model 
for end-stage liver disease (MELD) 8±1) and 12 post-LT 
patients with HCV recurrence (75% male; age 55±7, none 
with cirrhosis), were enrolled between January 2015 and 
June 2016, when they were scheduled to start treatment 
with DAAs (SOF+ribavirin (n=6 cirrhosis; n=9 post-LT), 
SOF+simeprevir (n=3 cirrhosis; n=3 post-LT) or SOF+le-
dipasvir (n=1 cirrhosis)), based on the Italian Drug 
Agency directives at the time. All were studied immedi-
ately prior to treatment commencement (baseline), at 
the end of the treatment course and after 6 months. At 
each time point, a full blood count, liver/kidney function 
tests, quantitative and qualitative HCV-RNA and venous 
ammonia levels were obtained. The Child-Pugh and 
MELD scores were calculated in patients with cirrhosis 
and the levels of immunosuppressants measured in 
post-LT patients. A summary of demographic and labora-
tory values is presented in table 1.
neuropsychiatric assessment
Patients underwent comprehensive neuropsychiatric 
evaluation to include a detailed medical history, exclu-
sion of concomitant neurological disorders and a clin-
ical grading of the neuropsychiatric abnormalities 
according to the West Haven criteria (vide infra), where 
appropriate. Procedures were performed under stan-
dardised conditions in the morning, after breakfast, in 
a quiet and well-lit room.
Paper and pencil psychometry
Number Connection Tests A and B, as well as the Digit 
Symbol, Line Tracing and Serial Dotting tests, were 
administered, and the results were scored in relation 
to age-adjusted and education-adjusted Italian norms. 
Performance was classified as impaired if the sum 
of the SD for the individual tests, referred to as the 
Psychometric Hepatic Encephalopathy Score (PHES), 
was ≤−4; the mean of the z scores for each subtest was 
also used for purposes of correlation analysis.7 8
Table 1 Demographic and laboratory values, by study group and study time
Cirrhosis Post-LT
T1
(n=10)
T2
(n=6)
T3
(n=5)
T1
(n=12)
T2
(n=10)
T3
(n=7)
Age 65.2±11.6 55.1±6.6*
Male/female 4/6 9/3
Education (years) 9.6±4.7 9.6±2.7
INR 1.1±0.2 1.0±0.1 1.0±0.1 1.0±0.1 1.1±0.1 1.1±0.1
Albumin (g/dL) 3.6±0.4 3.6±0.3 3.5±0.3 3.5±0.1 3.5±0.1 3.5±0.1
Total bilirubin 
(μmol/L)
25.0±21.8 12.2±8.9 11.0±4.2 17.9±9.3 14.2±9.0 16.0±8.1
Creatinine 
(μmol/L)
73.0±13.9 69.5±16.5 85.1±25.8 76.8±15.0 83.7±18.0 84.7±33.5
Ammonia 
(μmol/L)
29±22 21±9 16±11 31±36 22±17 33±22
Child class All A All A All A NA
MELD 9±3 7±1 8±1 NA
Fibrosis (kPa) NA NA NA 13.2±6.0
(n=12)
7.1±1.7
(n=10)
10
(n=1)
Genotype 
1/2/3/4
6/3/0/1 8/0/3/1
Comorbidities 
(treated)
2/10 Diabetes
2/10 Hypothyroidism
2/12 Diabetes
HCV-RNA+ (n/
total n)
10/10 1/10 2/10 12/12 0/12 0/12
HCV-RNA (UI/
mL)
1 807 755±1 892 805 1 731 839 822 624±1 127 659 7 661 900±13 906 807 NA NA
*P<0.05.
HCV, hepatitis C virus; LT, liver transplant; NA, not available; INR, international normalised ratio; MELD, model for end-stage liver disease. 
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Computerised psychometry: the Scan package
Simple reaction time
The subject is required to press the spacebar in the 
keyboard in response to a series of visual stimuli. The 
number of correct responses is expressed as a percentage 
of the total number of stimuli (accuracy), and the accu-
racy-adjusted, average, simple reaction time (ms) is 
calculated.
Choice reaction time
The subject is presented with either the number 1 or 3 
on the computer screen and is required to press 1 or 
3 on the keyboard accordingly. The number of correct 
responses is expressed as a percentage of the total 
number of stimuli (accuracy), and the accuracy-adjusted, 
average choice reaction time (ms) is calculated.
Scan reaction time
This is a digit recognition task based on the Sternberg 
paradigm. The subject is presented with a series of 36 
consecutive pairs of numbers and is asked to press 1 if 
they have common digits (ie, 3456 and 768) and 3 if not 
(ie, 123 and 789). The number of correct responses is 
expressed as a percentage of the total number of stimuli 
(accuracy), and the accuracy-adjusted, average Scan reac-
tion time (ms) is calculated.
The overall result of the Scan test is expressed as a z 
score, which is corrected for age and educational attain-
ment. z Scores ≤−2 are considered abnormal.9
Wake EEG
Electroencephalography (EEG) was recorded for 10 min, 
with eyes closed, in a condition of relaxed wakefulness, 
using a 21-electrode EEG cap. Electrodes were placed 
according to the International 10–20 system; the ground 
electrode was Fpz; the reference electrode was Oz; 
and impedance was kept below 5 k. Each channel had its 
own analogue-to-digital converter; the resolution was 0.19 
lV/bit (Brainquick 3200, Micromed, Mogliano Veneto, 
Italy). One continuous 80–100 s period of artefact-free 
EEG tracing was selected for subsequent spectral analysis 
by fast Fourier transform. The following spectral param-
eters were calculated on the P3-P4 derivation: the mean 
dominant frequency, which is an estimate of the back-
ground frequency of the EEG, and the relative power of 
the spectral bands delta (1–3.5 Hz), theta (4–8 Hz), alpha 
(8.5–13 Hz) and beta (13.5–25.5 Hz). EEGs were classi-
fied as normal/abnormal based on the spectral criteria 
proposed by Van der Rijt et al10 and subsequently modi-
fied by Amodio et al.11
In patients with cirrhosis, neuropsychiatric status was 
classified as unimpaired: no clinical evidence of hepatic 
encephalopathy (HE) and both normal PHES and 
normal EEG; covert HE: no obvious clinical abnormal-
ities (grade 0 or grade I according to the West Haven 
criteria)12 but abnormal PHES and/or EEG; and overt HE: 
clinically obvious neuropsychiatric disturbances (grade II 
or over according to the West Haven criteria).12 13 Scan 
test package abnormalities were described singly, and so 
were any neuropsychological or EEG abnormalities in 
post-LT patients.
statistical analysis
Results are expressed as mean±SD or ±95% CI. Variable 
distribution was tested using the Shapiro-Wilk’s test. 
Descriptive statistics and the Student’s t-test/Mann-
Whitney U tests were used, as appropriate, to compare the 
two groups. Differences in neuropsychological and elec-
trophysiological performance over time were compared 
by repeat-measures analysis of variance (ANOVA), by 
group. The latter analyses were performed for the six 
patients with cirrhosis/10 post-LT patients with available 
T1 and T2, and for the five patients with cirrhosis/seven 
post-LT patients with available T1, T2 and T3. In order 
to test for the possibility that ribavirin may have played 
a role, post-hoc factorial ANOVA (categorical predictors 
‘patient group’ and ‘ribavirin yes/no’) was performed on 
the two variables (relative delta power and choice reac-
tion time), which were shown to change significantly at 
T2.
ethics
All participants provided written, informed consent. The 
study was conducted according to the Declaration of 
Helsinki (Hong Kong Amendment) and Good Clinical 
Practice (European) guidelines.
results
Patients with cirrhosis were significantly older than 
post-LT patients (65±12 vs 55±7 years; P<0.05), while 
no differences were observed in terms of sex distribu-
tion (4/10 men in the cirrhosis group, 8/12 men in the 
post-LT group) and educational attainment (9.6±2.0 vs 
9.6±1.8) in the two groups. Sustained virological response 
was achieved in 80% and 100% of patients with cirrhosis 
and post-LT patients, respectively (table 1).
Table 2 Baseline Scan package performance, by patient 
group
Cirrhosis
(n=10)
Postliver 
transplant
(n=12)
Simple RT (ms) 374±93 346±66
Simple accuracy (%) 98.6±0.3 99.0±1.3
Choice RT (ms) 540±81 509±94
Choice accuracy (%) 98.6±2.3 97.3±3.6
Scan RT (ms) 1572±262 1468±186
Scan accuracy (%) 84±10 85±11
Scan-adjusted z score −0.8±1.3 −0.9±1.0
Mistakes (%) 10.3±6.3 8.8±5.0
Lapses (%) 5.5±6.4 5.4±10.8
RT, reaction time.
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Baseline (t1)
Seven out of the 12 post-LT patients had a history of 
overt HE prior to transplantation; none exhibited abnor-
malities on PHES, one had abnormal Scan test perfor-
mance (z score) and one showed grade I EEG slowing. By 
contrast, none of the patients with cirrhosis had a history 
of overt HE, none had overt HE at baseline, none had 
an abnormal PHES, one had abnormal Scan test perfor-
mance (z score) and three showed grade I EEG slowing. 
Average neuropsychological performances and EEG 
spectral parameters were comparable in the two groups 
at baseline, although slow EEG activity (theta) tended 
to be higher in patients with cirrhosis (<0.05<P<0.1) 
(tables 2–4).
end of treatment (t2)
Out of 22 patients enrolled, 16 underwent the second 
assessment (out of the six who did not, four were patients 
with cirrhosis, two of whom had been transplanted in the 
meantime). Out of the 10 post-LT patients evaluated at 
the end of treatment, none had abnormal PHES, none 
had an abnormal Scan test performance and one had 
grade I EEG slowing (same patient as in T1). Out of the 
six patients with cirrhosis evaluated at the end of treat-
ment, none had abnormal PHES, one had abnormal 
Scan test performance (same patient as in T1) and one 
had grade I EEG slowing (same patient as in T1). Taken 
as a group, patients with cirrhosis showed significant 
Figure 1 Mean (±95% CI) relative delta power at baseline 
and at the end of treatment in patients with cirrhosis (n=6, 
black circles) and post-transplant patients (n=10, grey 
squares). Patient group: P=0.031; time: P=0.025; patient 
group × time: P=0.011. EEG, electroencephalography.
Figure 2 Mean (±95%CI) relative delta power at baseline, 
at the end of treatment and 6 months after the end of 
treatment in patients with cirrhosis (n=5, black circles) 
and post-transplant patients (n=7, grey squares). Patient 
group: P=0.069; time: P=0.063; patient group × time: 
P=0.016. EEG, electroencephalography. 
Table 3 Baseline electroencephalography spectral 
parameters (P3-P4 derivation), by patient group
Cirrhosis
(n=10)
Postliver transplant
(n=12)
MDF (Hz) 11.2±1.6 11.6±1.4
Delta (%) 6.1±2.7 5.5±3.3
Theta (%) 24.0±14.0 15.1±10.9*
Alfa (%) 40.1±10.8 50.0±16.4
Beta (%) 29.8±12.4 29.4±15.2
MDF, mean dominant frequency.
*Trend 0.05<P<0.1.
Table 4 Number of patients with abnormal neuropsychological/electrophysiological performance at different time points, by 
group
Baseline
(n=10 cirrhosis, 12 post-
LT)
End of treatment
(n=6 cirrhosis, 10 post-LT)
End of treatment+6 months
(n=6 cirrhosis, 10 post-LT)
PHES Cirrhosis 0 0 0
Post-LT 0 0 0
EEG Cirrhosis 3 1* 0
Post-LT 1 1* 0
Scan package Cirrhosis 1 1* 1*
Post-LT 1 0 0
*Same patient as in previous evaluation (T1 or T2).
EEG, electroencephalogram; LT, liver transplant; PHES, Psychometric Hepatic Encephalopathy Score.
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slowing in choice reaction times and increased extra-
slow activity (relative delta power) on the wake EEG. In 
contrast, no significant changes were observed in the 
post-LT group (figure 1: 6 patients with cirrhosis and 10 
post-LT patients; and figures 2–3: 5 patients with cirrhosis 
and 7 post-LT patients).
end of treatment + 6 months (t3)
Out of 22 patients enrolled, 16 underwent the third assess-
ment (10 post-LT patients and 6 patients with cirrhosis). 
Out of the 10 post-LT patients evaluated at the end of 
treatment, none had abnormal PHES, Scan test or EEG. 
Out of the six patients with cirrhosis who were evaluated 
at T3, none had abnormal PHES, one had an abnormal 
Scan test performance (same patient as in T2) and none 
showed EEG slowing.
All three assessments were available for 12 patients 
(five with cirrhosis and seven post-LT). When quantitative 
neuropsychiatric measures were analysed over time, at T2 
(the end of the course of DAAs treatment) patients with 
cirrhosis exhibited a significant slowing in choice reac-
tion times and the EEG (increased relative delta power), 
which resolved after 6 months (P=0.01) (figures 2–3: five 
patients with cirrhosis and seven post-LT patients). At 
T2, three patients (two with cirrhosis and one post-LT) 
reported tiredness/irritability during the course of treat-
ment. Their performance did not appear to be different 
compared with that of patients who did not report symp-
toms, although formal subgroup analysis was not possible 
due to insufficient power.
No significant associations were observed between 
neuropsychiatric performance and stand-alone/
combined laboratory variables. In particular, no increase 
in ammonia levels was observed in patients with cirrhosis 
at T2 (table 1). Similarly, no changes were observed in 
immunosuppressive drug levels (all within the range) at 
different time points and no correlation was observed 
between such levels and neuropsychiatric performance 
in post-LT patients. Finally, while only two patients 
(both with cirrhosis) did not achieve sustained virologic 
response (SVR), their performance did not appear to 
be different compared with that of patients who did, 
although formal subgroup analysis was not possible due 
to insufficient power.
In order to test for the possibility that ribavirin may 
have played a role, post-hoc factorial ANOVA (categor-
ical predictors ‘patient group’ and ‘ribavirin yes/no’) 
was performed on the two variables (relative delta power 
and choice reaction time), which were shown to change 
significantly at T2. This did not confirm a role for riba-
virin, but power does not allow to reach definite conclu-
sions in this respect.
dIscussIon
Some degree of neuropsychiatric impairment was 
observed in relation to treatment with SOF-based regi-
mens in patients with cirrhosis, but not in post-LT 
patients, suggesting that the former may be more sensi-
tive to mild SOF-based regimens neurotoxicity.
At the end of a course of treatment with an SOF-based 
regimen, patients with cirrhosis exhibited an increase 
in extra-slow EEG activity and a slowing in their reaction 
times. None of them presented clinical features of overt 
hepatic encephalopathy and they showed no variations 
in either ammonia levels or MELD/Child-Pugh scores. 
Thus, it is unlikely that the cognitive changes recorded 
can be ascribed to hepatic encephalopathy. The alterations 
recorded at the end of treatment resolved at 6 months, 
possibly indicating mild SOF-based regimen neurotoxicity. 
Unfortunately, no evaluations were planned over the treat-
ment period (eg, at 4 or 8 weeks) for this study, which may 
have been of value. These may be considered for future 
research on the topic. Interestingly, it has been recently 
demonstrated that HCV eradication with DAAs leads to an 
improvement in neuropsychiatric performance over time 
(12 weeks from the end of treatment), suggesting that viral 
clearance itself may play a role.14 15 This, however, would 
not explain the transient neuropsychological and elec-
trophysiological worsening observed in our case series. 
Side effects such as weakness (30%–59%), headache 
(20%–30%), irritability (10%–16%) and depression (1%) 
have been reported in relation to treatment with SOF and 
may suggest mild neurotoxicity.16 In addition, while studies 
focusing specifically on the neuropsychiatric side effects of 
DAAs are lacking, preliminary data indicate, for example, 
that DAAs confer a minimal risk of additional side effects 
when taken together with antipsychotic drugs.17 There is 
a possibility that treatment with ribavirin may have also 
played a role. Ribavirin has been associated with headache 
and fatigue,18 and also with mood changes such as anxiety 
and depression. This case series does not support a role 
for ribavirin, but power does not allow to reach definite 
conclusions.
Figure 3 Mean (±95%CI) choice reaction time on the 
Scan package at baseline, at the end of treatment and 6 
months after the end of treatment in patients with cirrhosis 
(n=5, black circles) and post-transplant patients (n=7, grey 
squares). Patient group: P=0.048; time: P=0.200; patient 
group × time: P=0.083.
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In contrast to patients with cirrhosis, post-LT patients 
showed no significant variation in their neuropsychiatric 
performance over time. These differences may be explained 
by several factors: (1) age, as patients with cirrhosis were 
significantly older than their transplanted counterparts; 
(2) blood–brain barrier alterations, which are present in 
patients with cirrhosis19; (3) the known extreme sensitivity 
to the neurotoxic effects of both psychoactive and non-psy-
choactive drugs of patients with cirrhosis20 21; and (4) 
hepatic metabolism and hypoalbuminaemia,16 which may 
increase free drug levels. Finally, while the direct neuro-
toxicity of HCV infection remains debatable,22 23 it may be 
more likely to translate into a clinical phenotype in patients 
with cirrhosis rather than in healthier individuals with HCV 
infection only.
While cognitive impairment has been documented in 
transplanted patients and attributed to either immuno-
suppressive therapy24 or to the sequelae of previous liver 
failure/its aetiology,25 no significant cognitive alterations 
were detected in post-LT patients in this study at any time 
point.
In conclusion, we report mild, transient worsening in 
cognitive and neurophysiological performance in patients 
with cirrhosis at the end of a course of treatment with 
SOF-based regimens. Caution/monitoring may be needed 
in this group, especially if there is a history of overt hepatic 
encephalopathy and/or any neurological/psychiatric 
comorbidity. No such changes were observed in a group 
of younger but otherwise comparable patients treated for 
post-LT HCV recurrence. Our study has limitations, the 
main one being its size, which did not allow for subgroup 
and adjusted analyses. However, the presented results, 
together with the clinical experience of a small case series, 
suggest that further research into the neuropsychiatric 
effects of SOF-based regimens is worthy of further study. In 
particular, repeated neuropsychological and electrophysi-
ological evaluations during the course of treatment might 
be of value.
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